Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Official Title: MPS VI Clinical Surveillance Program (CSP)

The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

NCT00214773
Burton, Barbara K., MD
Observational
Yes

Contact Information:

Charlotte Dodsworth

Research Coordinator

312.227.6124